Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Monoclonal antibodies against dengue and other viruses with deletion in fc region

a dengue and other virus technology, applied in the field of immunology, can solve the problems of high fatality rate, and achieve the effect of reducing antibody-dependent enhancement (ade) and enhancing denv replication

Inactive Publication Date: 2013-12-26
THE U S AS REPRESENTED BY THE SEC DEPT OF HEALTH & HUMAN SERVICES
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a composition that prevents the enhancement of dengue virus replication in cells and in monkeys. The composition contains a peptide that has a deletion of at least one amino acid in a specific position. The peptide has lower affinity for a specific receptor called Fc gamma receptor, which is involved in antibody-dependent enhancement of dengue virus. The patent also describes a method for reducing antibody-dependent enhancement in a mammal and inducing complement-mediated neutralization or antibody-dependent cellular toxicity in a mammal. The technical effects of the patent are that it provides a way to prevent dengue virus infection and symptoms thereof, and that it identifies the key structures in the antibody that are responsible for antibody-dependent enhancement.

Problems solved by technology

Severe dengue is a major cause of hospitalization and has a high fatality rate, especially in children.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibodies against dengue and other viruses with deletion in fc region
  • Monoclonal antibodies against dengue and other viruses with deletion in fc region
  • Monoclonal antibodies against dengue and other viruses with deletion in fc region

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0166]Monoclonal Antibody-Mediated Enhancement of Dengue Virus Infection In Vitro and In Vivo and Strategies of Prevention

[0167]Infection with dengue virus (DENV) or any other flavivirus induces cross-reactive, but weakly- or non-neutralizing antibodies that recognize epitopes involving the fusion peptide in the envelope glycoprotein (E). Humanized monoclonal antibody (MAb) IgG 1A5, derived from a chimpanzee, shares properties of cross-reactive antibodies. MAb IgG 1A5 up-regulated DENV infection by a mechanism of antibody-dependent enhancement (ADE) in a variety of Fc receptor-bearing cells in vitro. A 10- to 1000-fold increase of viral yield in K562 cells, dependent on the DENV serotype, was observed over a range of sub-neutralizing concentrations of IgG 1A5. A significant increase of DENV-4 viremia titers (up to 100 fold) was also demonstrated in juvenile rhesus monkeys immunized with passively transferred dilutions of IgG 1A5. These results, together with earlier findings of ADE ...

example 2

Cultured Cells

[0188]Simian Vero cells and mosquito C6 / 36 cells were grown in Minimum Essential Medium (MEM). Human erythroleukemic K562 cells were grown in Iscove medium, myelomonocytic U937, Raji-1 (a B-cell line) and its derived Raji-1 (DC-SIGN) cells were grown in Advanced RPMI 1640 medium and 293 T cells were cultured in Dulbecco's Modified Eagle Medium. All media were supplemented with 10% fetal bovine serum (FBS), 0.05 mg / ml gentamycin, and 2.5 units / ml fungizone. Mammalian cells were propagated at 37° C. and C6 / 36 cells at 32° C. Media were purchased from Invitrogen and cells from American Type Culture Collection, except for cell lines Raji-1 and Raji-1 (DC-SIGN), which were kindly supplied by Dr. D. Littman, New York University School of Medicine.

Primary Monocytes

[0189]Mononuclear cells were separated from whole blood of rhesus monkeys by Ficoll-Hypaque gradient centrifugation, washed and resuspended in phosphate buffered saline (PBS) plus EDTA and 0.5% bovine serum albumin ...

example 3

Epitope Determinants of a Chimpanzee Dengue Virus Type 4 (DENV-4)-Neutralizing Antibody and Protection Against DENV-4 Challenge in Mice and Rhesus Monkeys by Passively Transferred Humanized Antibody

[0199]Chimpanzee Fab-derived monoclonal antibody (MAb) IgG 5H2 is specific for dengue type 4 virus (DENV-4) and able to neutralize the virus at a high titer in vitro. The epitope detected by the antibody was mapped by isolation and sequencing of antigenic variants of the virus. One variant contained a Lys174-Glu substitution and another contained a Pro176-Leu substitution in domain I of DENV-4 envelope protein (E). These closely spaced mutations reduced binding affinity to the antibody by 18 to >100 fold. Humanized IgG 5H2 produced from an expression vector has been shown to be a variant, containing a 9-aminoacid deletion in the Fc region which completely ablates the antibody-dependent enhancement activity of DENV replication in vitro. The variant MAb, termed IgG 5H2 ΔD, is particularly a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (FcγR) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.

Description

RELATED APPLICATIONS[0001]The present application is a continuation of U.S. patent application Ser. No. 12 / 594,756, filed Jun. 1, 2010, which is a National Stage application of PCT / US2008 / 059313, filed Apr. 3, 2008, which claims priority to U.S. Provisional Application Nos. 60 / 922,282, filed Apr. 4, 2007, 60 / 927,755, filed May 4, 2007, and 60 / 928,405 filed May 8, 2007, each of which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]Aspects of the present invention relate to immunology. More specifically, some embodiments include polypeptides comprising deletions in the Fc region and the use of these compositions for the treatment and prevention of disease.REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING[0003]The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled NIH355.001VPC.txt, created Apr. 1, 2008, which is 31 Kb in size. The information in the e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/10
CPCC07K16/1081A61K2039/505A61P31/12A61P31/14C07K2317/21C07K2317/24C07K2317/71C07K2317/76Y02A50/30
Inventor GONCALVEZ, ANA P.PURCELL, ROBERT H.LAI, CHING-JUH
Owner THE U S AS REPRESENTED BY THE SEC DEPT OF HEALTH & HUMAN SERVICES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com